Friday, May 24, 2019
Trovagene Inc. (TROV)
What a Preclinical Agreement Means
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Early Stage Development Agreement with Nektar Therapeutics. Trovagene announced a research and development agreement
with Nektar Therapeutics (NKTR, Not Covered) to assess Onvansertib in
combination with Onzeald (etirinotecan pegol) in preclinical colorectal cancer
model. - The basis of the agreement. The preclinical work includes two different colorectal cancer
models; BRAF-mutant and KRAS-mutant. Management stated that Nektar is
re…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
